Real world treatment utilization patterns in patients with castration-resistant prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Denis LJ, Carneiro De Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993;42(2):119–129.
   PubMed Web of Science ®Google Scholar
• Global Cancer Observatory, International Agency for Research on Cancer, World Health Organization. 2018. May 1, 2020]; Available from: https://gco.iarc.fr/
   Google Scholar
• Esther J, Maughan BL, Anderson N, et al. Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options Oncol. 2019;20(2):14.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355:i4405.
   PubMed Web of Science ®Google Scholar
• Boegemann M, Khaksar S, Bera G, et al. Abiraterone acetate plus prednisone for the management of metastatic castration-resistant prostate cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC Cancer. 2019;19(1):60.
   PubMed Web of Science ®Google Scholar
• Boni G, Mazzarri S, Cianci C, et al. (223)Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: real-world experience. Tumori. 2018;104(2):128–136.
   PubMed Web of Science ®Google Scholar
• Joshua AM, Shore ND, Saad F, et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate. 2015;75(8):836–844.
   PubMed Web of Science ®Google Scholar
• Maines F, Caffo O, Giorgi UD, et al. Safety and clinical outcomes of Abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian compassionate use named patient programme. Clin Genitourin Cancer. 2016;14(1):48–55.
   PubMed Web of Science ®Google Scholar
• Nakano K, Ohta S, Komatsu K, et al. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. BMC Urol. 2012;12(1):3.
   PubMedGoogle Scholar
• Pezaro CJ, Omlin AG, Altavilla A, et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;66(3):459–465.
   PubMedGoogle Scholar
• Sartor O, Vogelzang NJ, Sweeney C, et al. Radium-223 safety, efficacy, and concurrent use with Abiraterone or Enzalutamide: first U.S. experience from an expanded access program. Oncology. 2018;23(2):193–202.
   Google Scholar
• Shivji A, Ali R, North S, et al. Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract. 2019;25(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in trial and real-world populations in the Dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2018;4(5):694–701.
   PubMedGoogle Scholar
• George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–294.
   PubMed Web of Science ®Google Scholar
• Lissbrant IF, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593–1601.
   PubMed Web of Science ®Google Scholar
• Nordstrom T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003–2011. Eur Urol. 2013;63(3):419–425.
   PubMed Web of Science ®Google Scholar
• Aly M, Leval A, Schain F, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54:115–121.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Murad MH, Oh WK, et al. Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol. 2018;200(6):1264–1272.
   PubMed Web of Science ®Google Scholar
• Franck Lissbrant I, Ventimiglia E, Robinson D, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143–150.
   PubMed Web of Science ®Google Scholar
• Wen L, Valderrama A, Costantino ME, et al. Real-world treatment patterns in patients with castrate-resistant prostate cancer and bone metastases. Am Health Drug Benefits. 2019;12(3):142–149.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182–191.
   PubMed Web of Science ®Google Scholar
• Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48(4):546–551.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479.
   PubMed Web of Science ®Google Scholar
• Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–282.
   PubMed Web of Science ®Google Scholar
• Penson DF, Lin DW, Karsh L, et al. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Fut Oncol. 2016;12(23):2689–2699.
   PubMed Web of Science ®Google Scholar
• Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286–294.
   PubMed Web of Science ®Google Scholar
• Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5(2) :119–126.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar